Doptelet ® (avatrombopag) – Expanded indication, new formulation
July 25, 2025 - Sobi announced the FDA approval of Doptelet (avatrombopag), for the treatment of thrombocytopenia in pediatric patients 6 years and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.